Tuesday, April 08Hello, Sarah
The information universe, analyzed into what matters for you today
Action Items
for a repricing window in specialty pharmacy services — Elevance Health's Carelon restructuring is creating a 6–8 month dislocation that compresses multiples on three of your portfolio targets before the integrated model reprices them higher
Elevance Health announced a sweeping restructuring of Carelon, its health services unit, splitting pharmacy, behavioral health, and complex care into standalone P&Ls with independent boards. Bloomberg reports the move is designed to surface $3.2B in hidden margin across services that were previously cross-subsidized inside a single reporting segment. The structural consequence: specialty pharmacy operators that compete with Carelon's integrated bundle will see a temporary pricing advantage as Carelon's unbundled units lose cross-subsidy economics and must reprice to stand alone. Three companies in your active pipeline — BrightSpring, PharMerica, and Shields Health — all sit in this repricing zone.
↳ Changes if: Elevance reverses the restructuring or keeps Carelon's pharmacy unit bundled with behavioral health — which would preserve the cross-subsidy and eliminate the pricing dislocation entirely
Carelon's standalone P&Ls take effect Q3 2026. The repricing window — when specialty pharmacy competitors gain a cost advantage before Carelon's units stabilize — is approximately 6–8 months. Your diligence on BrightSpring and Shields needs to accelerate into that window or the multiple compression you're underwriting evaporates.
You've built your healthcare PE thesis around buying specialty services at 8–10x EBITDA during structural dislocations and exiting at 14–16x once the market recognizes the integrated value. The Carelon unbundling is creating exactly the kind of temporary multiple compression your fund was designed to exploit — but only if you move before the market connects the dots.
Whether CVS Health or Cigna announces a similar unbundling of their health services arms — which would confirm this is a structural industry shift, not an Elevance-specific event, and would significantly expand both your target list and the repricing window.
whether CMS's new site-neutral payment rule accelerates hospital system divestitures of outpatient surgical centers — your pipeline assumption of 4–6 actionable targets per quarter may need to double
CMS finalized its site-neutral payment expansion this week, eliminating the payment differential between hospital outpatient departments and ambulatory surgical centers for 12 additional procedure categories effective January 2027. Modern Healthcare estimates this removes $4.1B in annual revenue from hospital systems that depend on facility fee arbitrage. Health system CFOs are already modeling the margin impact — and for systems operating outpatient surgical centers at sub-scale volumes, divestiture math is about to flip from "explore" to "execute." The systems most exposed: mid-size regionals with 2–4 outpatient locations that lack the volume to offset the fee compression.
↳ Changes if: CMS delays implementation past January 2027 or carves out orthopedic and cardiac procedures — which would reduce the financial pressure on the exact surgical center categories you're targeting
The final rule published this week starts a 9-month clock before implementation. Health system boards will begin authorizing divestitures in Q3 2026 as they finalize 2027 budgets. Your fund has a narrow window to establish relationships with the CFOs making these decisions before competing PE firms read the same CMS announcement and crowd the same targets.
Your last two platform acquisitions — both outpatient surgical centers divested by regional health systems under margin pressure — followed this exact pattern: regulatory change compressed economics, boards authorized sales, and your fund moved in the 6-month window between announcement and competitive crowding. CMS just started the same clock again, at twice the scale.
Quarterly earnings calls from HCA, Tenet, and Community Health Systems in the next 30 days — any mention of "strategic alternatives" or "portfolio optimization" for outpatient assets is your leading indicator that divestiture mandates are being handed to bankers.
🔍 Flow Power Lens — The Bezos
Your actions in a different perspective.
Jeff Bezos built Amazon, AWS and more into a global powerhouse.
The real question isn't whether Carelon's unbundling creates a buying window — it's whether specialty pharmacy services are a commodity that gets cheaper every year or a platform that gets stickier with data. If BrightSpring and Shields are building patient-level outcomes databases that make switching costs compound over time, then the current multiple compression is a pricing error you can exploit for a decade. But if their margins depend on regulatory arbitrage rather than genuine lock-in, you're buying a melting ice cube at a slight discount. The CMS site-neutral rule tells you which one it is: the operators who maintain margins after facility fees disappear are the ones with real platform economics. The ones who don't were never worth 14x.
Flow is the actionable intelligence layer for professionals.
Was this useful? Reply to share feedback.
© Flow Information Systems